よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (43 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
99. Bassetti M, Echols R, Matsunaga Y. et al. Efficacy and safety of cefiderocol or best available
therapy for the treatment of serious infections caused by carbapenem-resistant Gramnegative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogenfocused, descriptive, phase 3 trial. Lancet Infect Dis. 2021 Feb;21(2):226-240.
100. Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S. Cefiderocol
Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa
Infections in the Compassionate Use Program. Antimicrob Agents Chemother. 2023
Jul;67(7):e0019423.
101. Timsit JF, Paul M, Shields RK. et al. Cefiderocol for the Treatment of Infections Due to
Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3
Randomized Studies. Clin Infect Dis. 2022 Sep;75(6):1081-1084.
102. Gill CM, Aktas E, Alfouzan W. et al. Elevated MICs of Susceptible Antipseudomonal
Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas
aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021
Oct;65(11):e0120421.
103. Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in
patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013
Jul;57(7):2907-2912.
104. Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas
aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect
Dis. 2007 Feb;44(3):357-363.
105. Hong LT, Downes KJ, FakhriRavari A. et al. International consensus recommendations for
the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of
Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis
Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious
Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious
Diseases Pharmacists. Pharmacotherapy. 2023 Aug;43(8):740-777.
106. Ramsey C, MacGowan AP. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother. 2016 Oct;71(10):2704-2712.
107. Moriyama B, Henning SA, Childs R. et al. High-dose continuous infusion beta-lactam
antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in
immunocompromised patients. Ann Pharmacother. 2010 May;44(5):929-935.
108. Vinks AA, van Rossem RN, Mathot RA, Heijerman HG, Mouton JW. Pharmacokinetics of
aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of doseexposure relationships using monte carlo simulation. Antimicrob Agents Chemother. 2007
Sep;51(9):3049-3055.
109. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful
pathogen. Clin Microbiol Rev. 2008 Jul;21(3):538-582.
110. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and
Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin
Microbiol Rev. 2017 Jan;30(1):409-447.
111. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant
Acinetobacter baumannii infections. Lancet Infect Dis. 2008 Dec;8(12):751-762.
43
第三版
別冊
99. Bassetti M, Echols R, Matsunaga Y. et al. Efficacy and safety of cefiderocol or best available
therapy for the treatment of serious infections caused by carbapenem-resistant Gramnegative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogenfocused, descriptive, phase 3 trial. Lancet Infect Dis. 2021 Feb;21(2):226-240.
100. Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S. Cefiderocol
Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa
Infections in the Compassionate Use Program. Antimicrob Agents Chemother. 2023
Jul;67(7):e0019423.
101. Timsit JF, Paul M, Shields RK. et al. Cefiderocol for the Treatment of Infections Due to
Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3
Randomized Studies. Clin Infect Dis. 2022 Sep;75(6):1081-1084.
102. Gill CM, Aktas E, Alfouzan W. et al. Elevated MICs of Susceptible Antipseudomonal
Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas
aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021
Oct;65(11):e0120421.
103. Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in
patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013
Jul;57(7):2907-2912.
104. Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas
aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect
Dis. 2007 Feb;44(3):357-363.
105. Hong LT, Downes KJ, FakhriRavari A. et al. International consensus recommendations for
the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of
Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis
Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious
Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious
Diseases Pharmacists. Pharmacotherapy. 2023 Aug;43(8):740-777.
106. Ramsey C, MacGowan AP. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother. 2016 Oct;71(10):2704-2712.
107. Moriyama B, Henning SA, Childs R. et al. High-dose continuous infusion beta-lactam
antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in
immunocompromised patients. Ann Pharmacother. 2010 May;44(5):929-935.
108. Vinks AA, van Rossem RN, Mathot RA, Heijerman HG, Mouton JW. Pharmacokinetics of
aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of doseexposure relationships using monte carlo simulation. Antimicrob Agents Chemother. 2007
Sep;51(9):3049-3055.
109. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful
pathogen. Clin Microbiol Rev. 2008 Jul;21(3):538-582.
110. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and
Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin
Microbiol Rev. 2017 Jan;30(1):409-447.
111. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant
Acinetobacter baumannii infections. Lancet Infect Dis. 2008 Dec;8(12):751-762.
43